



NECTAR LIFESCIENCES LIMITED

Sco 38-39, Sector 9 D, Madhya Marg, Chandigarh 160009, U.T., India

For immediate release

NecLife API Facility gets USFDA Approval

Chandigarh, 8 September, 2011

Nectar Lifesciences Limited (NecLife) has received US Food and Drug Administration's (USFDA) approval for its Active Pharmaceutical Ingredients (APIs) manufacturing plant Unit-II in Dera Bassi, Punjab. Followed by the recent audit of USFDA in June 2011 for its Drug Master File – Cefuroxime Axetil, NecLife received the confirmation of approval on 7th Sep 2011.

US market for Cefuroxime Axetil is currently valued at US\$ 50 Million and NecLife being the most integrated player globally stands to benefit with this approval through its associates.

NLL's API facility at Unit-II, Dera Bassi has also been approved by Japan MOH, MCC South Africa and Korean FDA. NecLife's API as well as Formulations Facility have both been successfully inspected by EU authorities and are awaiting final approval.

These approvals will help NecLife build and sustain the growth delivered by its API business by tapping the more profitable regulated markets.

So far, NecLife has filed 21 Drug Master Files (DMFs) in highly regulated markets and 6 Abbreviated New Drug Applications (ANDAs). The company expects to file another 20 DMFs and 10 ANDAs/EU Dossiers from Dera Bassi and Baddi facilities in this fiscal year.

About Nectar Lifesciences Limited (NeLife)

Established in 1995, NeLife (BSE code: 532649, NSE Id: NECLIFE, ISIN Id: INE023H01027) is a leading integrated pharmaceutical organization in India, offering a specialized comprehensive range of oral and sterile cephalosporin and Carbapenem active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The Company is growing presence in empty hard gelatine capsules (EHGCs) and menthol products. NeLife is one of the largest manufacturers of cephalosporin range of products and has an established brand presence in 20 states across India and 50 countries across five continents. NeLife has a global leadership position in 3 oral molecules and global No. 2 position in 2 sterile molecules. The Company has 11 manufacturing facilities – eight in Derabassi, Punjab (API and menthol units), two in Baddi, Himachal Pradesh (FDF and EHGC plants) and one in Jammu (menthol plant). NeLife's products include Oral and sterile cephalosporin, Carbapenem and other APIs, FDFs, Empty hard gelatin capsules and Menthol and allied products.

Additional information on NeLife is available on the Company website www.neclife.com.

Investor contacts

Dinesh Dua

Nectar Lifesciences Limited

Phone: +91 172 304 7766

Fax: +91 172 507 9049

Email: dinesh.dua@neclife.com

Note: This document contains 'forward-looking' statements at places. The Company has operations across several segments of business and remains subject to undetermined contingencies and risks. Nectar Lifesciences would not be liable for any action undertaken based on such 'forward-looking' statements and does not commit to revising/updating them publicly.